Regadenoson
Regadenoson is a selective adenosine A2A receptor agonist that causes coronary vasodilation and increases myocardial blood flow by activating A2A receptors on coronary arterial smooth muscle, simulating the physiological response to exercise stress. It is used as a pharmacological stress agent in myocardial perfusion imaging studies to diagnose coronary artery disease in patients unable to exercise adequately.
Masse moléculaire
390,3500 g/mol
LogP
-1,50
TPSA
186,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Structure 2D
Cite this structure
Embed this structure
SMILES
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O
InChI
InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1
Molecular Formula
C15H18N8O5
HBD / HBA
5 / 10
Liaisons Rotatives
4
Atomes Lourds
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Regadenoson is a selective adenosine A2A receptor agonist that causes coronary vasodilation and increases myocardial blood flow by activating A2A receptors on coronary arterial smooth muscle, simulating the physiological response to exercise stress. It is used as a pharmacological stress agent in myocardial perfusion imaging studies to diagnose coronary artery disease in patients unable to exercise adequately.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Regadenoson is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989695. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 219024. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="regadenoson"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/regadenoson/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/regadenoson/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/regadenoson/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="regadenoson"></drugfyi-drug>